ZIVO BIOSCIENCE, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
ZIVO BIOSCIENCE, INC. (ZIVO) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $1.68 million as of 2021-09-30, per its 10-Q/A filed 2022-04-21.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2022-04-21
- 2021-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.68M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2021-09-30 | $1.68M 10-Q/A · filed 2022-04-21 |